Suffer from Long-Lasting Chronic Rhinosinusitis?
Find out if you qualify for a clinical trial that could help.
Chronic rhinosinusitis (CRS) happens when your sinuses — the space inside your nose and head — are swollen and inflamed for more than 12 weeks. CRS affects up to 12% of people in the US, and typically causes symptoms such as facial pain or pressure, nasal congestion, nasal discharge and/or decreased sense of smell.
Biohaven Pharmaceuticals is conducting a clinical trial to investigate the potential of rimegepant — a medicine currently FDA-approved for migraine in adults — to treat acute symptoms of CRS with or without nasal polyps.
You may be eligible to participate if you:*
*Study clinicians will further assess medical history to determine eligibility.
Health insurance is not required to participate in this study and the investigational drug, plus all study-related assessments and care will be provided at no cost to you.
What does taking part in the study involve?
The study will consist of three visits and the total length of participation may be up to 66 days. Participants will receive active medication (rimegepant) or placebo.
Are participants compensated for the study?
Compensation for time and travel may be provided.